Trial Profile

Dasatinib (BMS-354825) Combined With SMO Inhibitor (BMS-833923; XL139) in CML With Resistance or Suboptimal Response to a Prior TKI.

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BMS 833923 (Primary) ; Dasatinib (Primary)
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Biomarker
Sponsors Bristol-Myers Squibb

Most Recent Events

01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
14 Mar 2013 Planned end date changed from 1 Jan 2015 to 1 Apr 2013 as reported by ClinicalTrials.gov.
01 Feb 2013 Planned end date changed from 1 Jun 2015 to 1 Jan 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com